Yoon-Hee Hong

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Ivana Yen, Jeeyun Lee, Yong Sang Hong et al. · Nature · 2021 · 133 citations · Full text

Raf Inhibitor Belvarafenib, Melanoma, Pathology +6

Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

Tae Won Kim, Jeeyun Lee, Sang Joon Shin et al. · Journal of Clinical Oncology · 2019 · 46 citations

Chemoprevention Strategy, Quantitative Pharmacology, Solid Tumor Patients +19

Flavonoids from the flower ofRhododendron yedoense var.Poukhanense and their antioxidant activities

Sung Je Jung, Dong‐Hyun Kim, Yoon-Hee Hong et al. · Archives of Pharmacal Research · 2007 · 41 citations

Medicine, Phytopharmacology, Antioxidant Activities +4

A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.

Sang Joon Shin, Jeeyun Lee, Tae Min Kim et al. · Journal of Clinical Oncology · 2021 · 29 citations

Phase Ib Trial, Pharmacotherapy, Metronomic Therapy +17

A Role for the Carbohydrate Portion of Ginsenoside Rg3 in Na+ Channel Inhibition

Jong‐Hoon Kim, Yoon-Hee Hong, Jun‐Ho Lee et al. · Molecules and Cells · 2005 · 27 citations · Full text